Agreement between anti-Xa, APTT and ACT assays for results below, within, and above therapeutic ranges for samples after administration of UFH
| . | anti-Xa . | ||
|---|---|---|---|
| aPTT . | <0.35 U/mL . | 0.35-0.7 U/mL . | >0.7 U/mL . |
| >85 s | 38 (16%) | 82 (33%) | 97 (39%) |
| 60-85 s | 15 (6%) | 0 (0%) | 0 (0%) |
| <60 s | 14 (6%) | 0 (0%) | 0 (0%) |
| . | anti-Xa . | ||
|---|---|---|---|
| aPTT . | <0.35 U/mL . | 0.35-0.7 U/mL . | >0.7 U/mL . |
| >85 s | 38 (16%) | 82 (33%) | 97 (39%) |
| 60-85 s | 15 (6%) | 0 (0%) | 0 (0%) |
| <60 s | 14 (6%) | 0 (0%) | 0 (0%) |
| . | anti-Xa . | ||
|---|---|---|---|
| ACT . | <0.35 U/mL . | 0.35-0.7 U/mL . | >0.7 U/mL . |
| >250 s | 0 (0%) | 3 (1%) | 34 (15%) |
| 150-250 s | 7 (3%) | 41 (18%) | 51 (23%) |
| <150 s | 53 (24%) | 29 (13%) | 6 (3%) |
| . | anti-Xa . | ||
|---|---|---|---|
| ACT . | <0.35 U/mL . | 0.35-0.7 U/mL . | >0.7 U/mL . |
| >250 s | 0 (0%) | 3 (1%) | 34 (15%) |
| 150-250 s | 7 (3%) | 41 (18%) | 51 (23%) |
| <150 s | 53 (24%) | 29 (13%) | 6 (3%) |
| . | ACT . | ||
|---|---|---|---|
| aPTT . | <150 s . | 150-250 s . | >250 s . |
| >85 s | 62 (28%) | 98 (44%) | 37 (17%) |
| 60-85 s | 14 (6%) | 0 (0%) | 0 (0%) |
| <60 s | 13 (6%) | 0 (0%) | 0 (0%) |
| . | ACT . | ||
|---|---|---|---|
| aPTT . | <150 s . | 150-250 s . | >250 s . |
| >85 s | 62 (28%) | 98 (44%) | 37 (17%) |
| 60-85 s | 14 (6%) | 0 (0%) | 0 (0%) |
| <60 s | 13 (6%) | 0 (0%) | 0 (0%) |
Cells show absolute numbers (% of total number of samples: n = 246 for anti-Xa vs APTT; n = 224 for anti-Xa vs ACT and APTT vs ACT). Concordant cells are bold.